Glycosphingolipids are components of the outer leaflet of the plasma membrane of mammalian cells. The functions of glycosphingolipids are pleiotropic and have been implicated in many important processes, including cellular growth and differentiation (1) . Glycosphingolipids have been shown to modulate signal transduction and therefore the mechanisms underlying the regulation of these signaling processes by glycosphingolipids have been the focus of many studies. Glycosphingolipids are clustered and contribute to the formation of microdomains in association with cholesterol and sphingomyelin (2) . These lipid rafts have been implicated in signal transduction based on the colocalization of many types of signaling molecules within these rafts. These signaling molecules include receptors (3) (4) (5) , phosphoinositides (6) , non-receptor tyrosine kinases (7), GTPbinding proteins (8) , and adaptor proteins (9, 10) .
In previously reported work, glycosphingolipids were shown to regulate phospholipase C-␥1 activity within lipid rafts (11) . Specifically, the depletion of glucosylceramide and other glucosylceramide-based glycosphingolipids in ECV304 cells was marked by increased phospholipase C activity and inositol trisphosphate formation. The increase in phospholipase activity was the result of phosphorylation and not expression of the lipase. The increase in phosphorylation and activity was observed under both basal conditions and in response to stimulation with bradykinin. ECV304 cells were originally characterized as a human endothelial cell line but have characteristics that are more consistent with those of a bladder carcinoma cell line. ECV304 cells were used in this study, because they demonstrate a high rate of turnover of glycosphingolipids and have many lipid raft-associated signaling molecules, including bradykinin and EGF 1 receptors, c-Src, and phospholipase C-␥1 (11) .
The mechanism responsible for the glycosphingolipiddependent change in phospholipase C activity remains to be elucidated. Indeed, phospholipase C-␥1 is phosphorylated and activated in response to a receptor tyrosine kinase such as EGF and recruited to the inner membrane during cell signaling. Glycosphingolipids, on the other hand, are present in the outer leaflet. A direct interaction between phospholipase C-␥1 and a glucosylceramide-based glycolipid is unlikely to account for these observations. In the present study, ECV304 cells were employed to further investigate the basis for the observed increase in phospholipase C-␥1 activity in the setting of glycosphingolipid depletion.
EXPERIMENTAL PROCEDURES
Materials-Rabbit polyclonal antibodies against human c-Src (pY418), c-Src (pY529), human EGF receptor (pY1068), human EGF receptor (pY1148), and human EGF receptor (pY1173) were purchased from BioSource (Camarillo, CA). PP2, AG1478, and mouse monoclonal antibody to human c-Src protein were obtained from Calbiochem (La Jolla, CA). Rabbit polyclonal anti-phosphotyrosine antibody, mouse monoclonal anti-human EGF receptor antibody, recombinant pp60 c-Src enzyme, synthetic c-Src substrate peptide (KVEKIGEGTYGVVYK), and P81 phosphocellulose paper were acquired from Upstate Biotechnology Inc. (Lake Placid, NY). Mouse monoclonal anti-phospholipase C-␥1 antibody was from BD Pharmingen (San Diego, CA), and * This work was supported by National Institutes of Health Grant RO1-DK55823 (to J. A. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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[␥-32 P]ATP was from PerkinElmer Life Sciences. Protein A-agarose, EGF, and bradykinin were purchased from Sigma Chemical Co. (St. Louis, MO). D-t-EtDO-P4 and D-e-EtDO-P4 enantiomers were synthesized and isolated as previously described (12) .
Cell Culture-Human ECV304 cells were routinely maintained in Medium 199 (M199) supplemented with 10% (v/v) newborn calf serum, 2 mM L-glutamine, 4.5 g/liter D-glucose, 100 g/ml streptomycin, and 100 units/ml penicillin. For lipid extraction, cells were plated onto 150-mm dishes. For immunoprecipitation, Western blotting analysis, and Src kinase activity measurements, the cells were plated onto 100-mm dishes. The cells were grown for 2 days to 85-90% confluence prior to treatment with glucosylceramide synthase inhibitors. The medium containing 10% serum was removed and replaced with serum-free M199 medium with or without the glucosylceramide synthase inhibitors. Stock solutions of D-t-EtDO-P4 and D-e-EtDO-P4 (4 mM) were made in 100% Me 2 SO and diluted with 250 volumes of serum-free M199 medium just prior to use. Equivalent Me 2 SO concentrations served as vehicle controls. All cells were maintained at 37°C in a humidified 5% CO 2 atmosphere. The normal morphology of cells and the total protein content of cultured cells were unaffected by treatment with up to 3 M D-t-EtDO-P4 for 48 h.
Immunoprecipitation and Immunoblotting-Serum-starved ECV304 cells in the presence or absence of D-t-EtDO-P4 or D-e-EtDO-P4 were exposed to either bradykinin, EGF, PP2, or AG1478 at various concentrations and time intervals. The exposures were stopped by aspiration of the incubation medium. Cells were then rinsed twice with ice-cold phosphate-buffered saline containing 1 mM Na 3 VO 4 and lysed in 1 ml of ice-cold Tris-Triton lysis buffer (25 mM Tris-HCl (pH 7.4), 1% Triton X-100, 10% glycerol, 20 mM NaF, 2 mM EDTA, 2 mM Na 3 VO 4 , 137 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, 20 g/ml aprotinin, and 1 g/ml pepstatin). Insoluble debris was removed by centrifugation at 21,000 ϫ g for 20 min at 4°C. Protein concentrations were determined by use of the bicinchoninic acid assay using bovine serum albumin as a standard. Immunoprecipitation and immunoblots were performed as previously described (13) . Briefly, equal amounts of protein from each cell lysate were incubated with selected antibodies at 4°C for 2 h or subjected to direct Western blotting. Immunoprecipitates were absorbed by protein A-agarose beads and washed with ice-cold washing buffer (25 mM Tris-HCl (pH 7.4), 0.1% Triton X-100, 1 mM Na 3 VO 4 , 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 5 g/ml leupeptin, 10 g/ml aprotinin, and 1 g/ml pepstatin). The immunoprecipitates or whole cell extracts were resolved by SDS-PAGE using a 4 -13% gradient and transferred to a nylon membrane. The blots were blocked overnight at 4°C in 5% skimmed milk in TBS buffer (20 mM Tris-HCl (pH 7.6), 150 mM NaCl) and probed with selected antibodies diluted in TBS containing 1% skimmed milk. The immunoreactive bands were detected with the ECL-plus system (PerkinElmer Life Sciences).
Src Dephosphorylation, Phosphorylation, and in Vitro Kinase Assays-The measurement of Src dephosphorylation was performed by immunoprecipitation combined with immunoblotting. The clarified cell lysates (200 g of protein) were incubated with a monoclonal antihuman Src antibody (2 g/200 g of lysate protein) for 2 h at 4°C. The anti-Src immunocomplexes were then immobilized on protein A-agarose beads. The recovered samples were washed four times with washing buffer, solubilized in SDS sample buffer, electrophoresed, and immunoblotted with a rabbit polyclonal anti-phosphotyrosine antibody that specifically recognizes the carboxyl-terminal (TSTEPQpYQPGENL) sequence of human c-Src, corresponding to the sequence surrounding the Tyr-529 residue. Alternatively, equal amounts of total cellular lysate protein (30 g) were directly subjected to Western blotting and probed with a polyclonal phosphospecific anti-human Src (pY529) antibody (0.25 g/ml). The phosphotransferase activity of Src kinase was assayed in parallel by incubation of cell lysates (500 g of protein) with a mouse antibody against human Src kinase (4 g/ml). The Src immunoprecipitates were washed three times in ice-cold washing buffer (50 mM TrisHCl (pH 7.2), 10 mM MgCl 2 , 2 mM EGTA, 100 M Na 3 VO 4 , and 1 mM dithiothreitol). The washed immunocomplexes were then incubated in 30 l of kinase reaction buffer (50 mM Tris-HCl (pH 7.2), 10 mM MgCl 2 , 10 mM MnCl 2 , 2 mM EGTA, 100 M Na 3 VO 4 , and 1 mM dithiothreitol) supplemented with 150 M synthetic peptide (KVEKIGEGTYGVVYK) as exogenous substrate. The kinase reactions were initiated by the addition of 8 M [␥-32 P]ATP (8 Ci) in 10 l of Src Mn/ATP mixture (50 mM Tris-HCl (pH 7.2), 25 mM MnCl 2 , 100 M ATP, 25 mM ␤-glycerol phosphate, 2 mM EGTA, 100 M Na 3 VO 4 , and 1 mM dithiothreitol). The assays were run at 30°C for 10 min with agitation and terminated by the addition of 30 l of 50% acetic acid (v/v). The samples were centrifuged, and the supernatants were spotted onto P81 ion exchange chromatography paper. The paper squares were washed five times for 5 min each in 0.75% phosphoric acid, once in acetone, and then air dried. The phosphotransferase activity of human Src was measured as specific 32 P incorporation into the substrate (KVEKIGEGT( 32 pY)GVVYK) by liquid scintillation counting. Alternatively, rabbit muscle enolase was used as an exogenous substrate. The enolase phosphorylation by Src kinase was assessed by the incubation of whole cellular lysate (500 g of protein) with a mouse monoclonal anti-human Src antibody (4 g/500 g of protein) as described above. The precipitated immunocomplexes were incubated with 30 l of kinase reaction buffer with 2.5 g of aciddenatured enolase and 8 M [␥-32 P]ATP (8 Ci) at 30°C for 10 min. The assays were terminated by the addition of 2ϫ SDS loading buffer. The products were resolved on a 4 -13% gradient SDS-PAGE. The acrylamide gel was dried, and the 32 P-labeled enolase was visualized by autoradiography.
Lipid Extraction and Analysis-ECV304 cells that were treated or untreated with glucosylceramide synthase inhibitors were washed with ice-cold phosphate-buffered saline, fixed with ice-cold methanol, and harvested by scraping. Chloroform was then added to yield a theoretical ratio of chloroform:methanol:water at 1:2:0.8 (v/v). The mixture of cells, chloroform, and water was sonicated for 15 min in a bath sonicator and centrifuged at 2200 ϫ g for 30 min. The resultant supernatants were partitioned into aqueous and organic phases by the addition of chloroform and water to create a ratio of chloroform:methanol:water (2:1:0.8, v/v). The lower organic phases were carefully extracted, washed with 0.9% NaCl, and evaporated under a stream of nitrogen gas. The residues were redissolved into a chloroform/methanol solution (2:1, v/v). Total cellular phospholipid was measured with a lipid phosphate assay. For the analysis of glucosylceramide, equal amounts of total lipid phosphate (150 nmol) from each sample were subjected to base hydrolysis by incubation with 2 ml of chloroform and 1 ml of 0.21 N NaOH in 100% methanol at 37°C for 1 h. The incubation was terminated by the addition of 0.8 ml of 0.3 M acetic acid. Glucosylceramide was extracted from the lower organic phase, dried under a stream of nitrogen gas, and analyzed by high performance thin layer chromatography with a solvent system consisting of chloroform:methanol:water (65/25/4, v/v), and detected by charring with 8% cupric sulfate in 8% phosphoric acid. The levels of glucosylceramide were quantified by densitometric scanning using Image version 1.62 (National Institutes of Health) and compared with authentic standards run in parallel on the same plates.
RESULTS
The concentration-dependent depletion of glucosylceramide by D-t-EtDO-P4 was compared with the inactive enantiomer, D-e-EtDO-P4. Quiescent cultures of ECV304 cells were exposed to either D-t-EtDO-P4 or D-e-EtDO-P4 at 50, 100, and 200 nM for 24, 36, or 48 h. The glucosylceramide mass in each cell culture was determined by thin layer chromatography and normalized to total phospholipid phosphate ( Fig. 1) . By 48 h, greater than 99% depletion of glucosylceramide was observed in D-t-EtDO-P4-treated cells at inhibitor concentrations between 50 and 100 nM. However, the glucosylceramide levels were not affected in the cells treated with D-e-EtDO-P4 at the same or even higher concentrations. These data are consistent with the previously reported specificity of the R,R-enantiomer for inhibition of glucosylceramide synthase.
The possibility that activation of c-Src kinase, a non-receptor protein-tyrosine kinase, may mediate the tyrosine phosphorylation of phospholipase C-␥1 observed with glucosylceramide depletion of ECV304 cells was studied. The phosphotransferase activity of c-Src kinase was measured as the capacity of c-Src immunoprecipitated from cell lysates to phosphorylate a c-Srcspecific substrate peptide (KVEKIGEGTYGVVYK) (Fig. 2) . The activities of Src kinase from immunoprecipitates of cells treated with D-e-EtDO-P4 showed no difference compared with untreated control cells. In contrast, Src kinase activity from immunoprecipitates of D-t-EtDO-P4-treated cells exhibited a dose-dependent increase. The maximal increase in the Src kinase activity was observed in the cells exposed to 100 nM D-t-EtDO-P4. An increase of D-t-EtDO-P4 concentrations over 100 nM, however, led to a decrease in the Src kinase activities to basal levels. The basal levels of kinase activities were pro-gressively lower as the cells were maintained in serum-free medium. However, the peak increase in kinase activity was not significantly different between cells grown for 24, 36, and 48 h in the absence of serum. In addition, the direct addition of either D-t-EtDO-P4 or D-e-EtDO-P4 to the assay mixture was without effect on Src kinase activity.
The coupling of bradykinin stimulation of ECV304 cells to Src kinase activation was next studied. More specifically, the effects of bradykinin on the dephosphorylation of Src kinase at tyrosine residue 529 (Tyr-529), the inhibitory site within the C-terminal regulatory region, and the phosphorylation of c-Src kinase at tyrosine residue 418 (Tyr-418), the activation site, within the catalytic loop was evaluated in control cells and in cells treated with 100 nM D-t-EtDO-P4 (Fig. 3A) . Western blot analysis revealed that the depletion of glucosylceramide by D-t-EtDO-P4 (100 nM) in cultured ECV304 cells induced autodephosphorylation of c-Src at the Tyr-529 residue and autophosphorylation of c-Src at the Tyr-418 residue. Upon stimulation with bradykinin, a rapid and transient dephosphorylation of Src at Tyr-529 and phosphorylation of Src at Tyr-418 was observed in control cells. These changes were dependent on the dose and time of bradykinin exposure. In glucosylceramide-depleted cells, both Tyr-529 dephosphorylation and Tyr-418 phosphorylation of c-Src kinase were significantly enhanced and markedly extended. The total cellular expression of c-Src was no different in the absence or presence of the glucosylceramide synthase inhibitor, bradykinin, or both.
The phosphotransferase activities of Src kinase were assayed in vitro in parallel experiments (Fig. 3B) . Bradykinin induced an increase in the Src kinase activity in both control and in cells treated with 100 nM D-t-EtDO-P4. The basal and stimulated Src kinase activities were higher in the inhibitor-treated cells, and the stimulated kinase activity displayed a peak activity at 1 min versus 30 s. The pattern of Src kinase activation was similar in the control and D-t-EtDO-P4-treated cells.
The association between glucosylceramide depletion and Src kinase activity was studied further with the c-Src kinase inhibitor PP2 (Fig. 4) . Serum-starved cells incubated with or without 100 nM D-t-EtDO-P4 for 24 h were exposed to 0.1, 0.5, and 1.0 M PP2 for another 12 h (Fig. 4A) . The phosphorylation status of c-Src kinase at Tyr-529 residue was detected by immunoprecipitation with a monoclonal anti-human Src antibody, followed by immunoblot analysis using a polyclonal antibody recognizing the c-Src carboxyl-terminal sequence (TSTEPQpYQPGENL) surrounding the Tyr-529 residue. In the case of controls, cells exposed to a relatively low dose of PP2 (0.1 M) for 12 h maximally restored phosphorylation of c-Src kinase at the carboxyl-terminal inhibitory tyrosine residue, Tyr-529. However, glucosylceramide-depleted cells were observed to be insensitive to PP2 treatment. The dose-dependent phosphorylation of human c-Src at Tyr-529 by PP2 was shifted rightward in D-t-EtDO-P4-treated cells. The phosphorylation in D-t-EtDO-P4-treated cells was observed in those cells exposed to a relatively high dose of PP2 (1.0 M) for 12 h. By contrast, the phosphorylation of c-Src kinase at Tyr-418 residue (the activation site) within the catalytic loop was gradually decreased in control and in D-e-EtDO-P4-treated cells with even greater PP2 concentrations (5, 10, and 15 M for 2 h) (Fig. 4B) . Under the same experimental conditions, D-t-EtDO-P4- treated   FIG. 3 . Enhancement of Src dephosphorylation, phosphorylation, and kinase activity inducted by bradykinin in glycosphingolipid-depleted ECV304 cells. Serum-starved cells untreated or treated with D-t-EtDO-P4 (100 nM) for 48 h were stimulated with 0.5 or 1 M bradykinin for different times as indicated. The clarified cell lysates were directly subjected to Western blots and analyzed by specific antibodies. In A: upper panel, the membrane was probed using a polyclonal phosphospecific anti-human Src (pY529) antibody. Middle panel, the membrane was probed using a polyclonal phosphospecific anti-human Src (pY418) antibody. Lower panel, the membrane was probed using a monoclonal anti-human Src antibody. The blots were representative of three independent experiments each performed using three independent cell cultures. In B: the activities of Src kinase in cells stimulated with 1 M bradykinin were assessed in parallel using a specific Src substrate peptide (KVEKIGEGTYGVVYK) as an exogenous substrate. The data represent the mean Ϯ S.D. of three experiments performed in duplicate.
FIG. 4. Resistance of Src kinase to the Src inhibitor PP2 in glucosylceramide-depleted ECV304 cells.
In A: upper panel, quiescent cells incubated with or without 100 nM D-t-EtDO-P4 for 24 h were exposed to PP2 at the indicated concentrations for another12 h. Human Src (200 g of lysate protein) was immunoprecipitated with monoclonal anti-human Src antibody (4 g/ml) and probed with an anti-phosphotyrosine antibody that specifically recognizes human c-Src C-terminal sequence (TSTEPQpYQPGENL). Lower panel, the total cellular expression of c-Src was quantified by immunoblotting analysis in parallel using the identical samples. Upper panel, whole cell lysates were obtained from control cells and cells treated with D-t-EtDO-P4 for 34 h followed by the addition of PP2 for 2 h. The lysates were directly subjected to immunoblotting using a phosphospecific anti-human Src (pY418) antibody. In B: lower panel, the total cellular expression of Src was determined by Western blotting in parallel using the identical samples. C, cells were incubated with or without D-t-EtDO-P4 (100 nM) for 34 h and then exposed to PP2 for another 2 h at different concentrations as indicated. Src kinase in 500 g of lysate protein was immunoprecipitated with a mouse monoclonal anti-Src antibody (4 g/ml). The activity was assayed using rabbit muscle enolase as an exogenous substrate. The cells were resistant to the inhibitory effect of PP2 on phosphorylation of c-Src kinase at Tyr-418. This resistance was still observed at the highest concentration of PP2 employed in this study. The activities of Src kinase were assayed in vitro in parallel experiments using rabbit muscle enolase as an exogenous substrate (Fig. 4C) . The measured change in c-Src kinase activities paralleled those predicted by the change in phosphorylation status under the identical experimental conditions. D-e-EtDO-P4-treated cells demonstrated no change in c-Src kinase activity with the rabbit enolase substrate (Fig. 4D) .
Bradykinin stimulation of phospholipase C-␥1 activity may be mediated via activation of the EGF receptor. Therefore, the effect of glucosylceramide depletion on bradykinin-stimulated phosphorylation of the EGF receptor was next evaluated. The cells were deprived of serum, and growth factors for 48 h and total cell lysates were subjected to Western blot analysis using two phosphospecific antibodies: anti-human EGF receptor (pY1068) and anti-human EGF receptor (pY1173) (Fig. 5) . Under control conditions, no background phosphorylation at either Tyr-1068 or Tyr-1173 was observed. However, in glucosylceramide-depleted cells, tyrosine phosphorylation of the EGF receptor was detected at Tyr-1068 but not at Tyr-1173. In control cells, bradykinin induction phosphorylated the EGF receptor at carboxyl-terminal Tyr-1068 and Tyr-1173 residues in a dose-and time-dependent manner. The pretreatment of ECV304 cells with D-t-EtDO-P4 resulted in the enhanced phosphorylation of the Tyr-1068 residue but impaired phosphorylation of the Tyr-1173 residue. No changes in the total cellular expression of the EGF receptor were observed under these conditions.
Phospholipase C-␥1 is a substrate for the EGF receptor tyrosine kinase. Therefore, the phosphorylation of phospholipase C-␥1 was studied in response to stimulation with EGF in the presence and absence of D-t-EtDO-P4 treatment (Fig. 6, A and  B) . EGF stimulation induced a time-and concentration-dependent increase in phospholipase C-␥1 phosphorylation. In the presence of D-t-EtDO-P4, the degree of phosphorylation, the rapidity of the response, and the duration of the phosphorylation were increased.
In the presence of the c-Src inhibitor, PP2, the tyrosine phosphorylation of phospholipase C-␥1 in response to EGF was attenuated (Fig. 7A) . This attenuation was reversed by glucosylceramide depletion with D-t-EtDO-P4 (Fig. 7B) . These results suggest that Src kinase functionally contributes to the tyrosine phosphorylation of phospholipase C-␥1 during cell stimulation with both EGF and bradykinin.
Because differences in the sensitivity of carboxyl-terminal residues of the EGF receptor to glucosylceramide depletion were observed in response to bradykinin, tyrosine phosphorylation was also studied in response to EGF stimulation (Fig. 8) . Whole cell lysates prepared from control cells and cells pretreated with D-t-EtDO-P4 cells that were then simulated with EGF were analyzed by Western blot employing four different phosphospecific antibodies. These antibodies included anti-human EGF receptors pY1068, pY1086, pY1148, and pY1173. Tyrosine phosphorylation in response to EGF was observed at each residue. In each case phosphorylation was inhibited with AG1478. In glucosylceramide-depleted cells, the EGF receptor tyrosine phosphorylation was significantly elevated in response to EGF stimulation at Tyr-1068 and to a lesser extent at Tyr-1086. Similar effects from glycolipid depletion were not observed at Tyr-1148 or Tyr-1173. D-t-EtDO-P4 partially re- Equal amounts of whole cell lysate were subjected to Western blot analysis. Upper panel, the membrane was loaded with 30 g of lysate protein and probed with a polyclonal phosphospecific anti-human EGF receptor (pY1068) antibody. Middle panel, the membrane was loaded with 30 g of lysate protein and was probed with a polyclonal phosphospecific anti-human EGF-R (pY1173) antibody. Lower panel, the membrane was loaded with10 g of lysate protein and probed with a monoclonal anti-human EGF-R antibody. The immunoreactive bands were detected using the ECL-plus system. The blots are representative of three independent experiments.
FIG. 6. EGF stimulation of glucosylceramide-depleted ECV304 cells enhances the tyrosine phosphorylation of PLC-␥1.
Control and D-t-EtDO-P4-treated cells (100 nM for 48 h) were stimulated with or without EGF for different times. The stimulations were stopped by aspiration of the incubation medium. Cell lysates were prepared as described under "Experimental Procedures." Phospholipase C-␥1 in each cell lysate sample (500 g of protein) was immunoprecipitated with a rabbit polyclonal anti-phosphotyrosine antibody (4 g/ml). The precipitated immunocomplexes (upper panels) were analyzed by Western blot after SDS-PAGE (4 -13%) separation. The membranes were probed with a mouse monoclonal antibody against phospholipase C-␥1 (0.1 g/ml). The cellular expression of phospholipase C-␥1 (10 g of lysate protein) was detected by Western blot (lower panels). A, cells were stimulated with EGF (20 ng/ml) for different time points. B, cells were stimulated with EGF (50 ng/ml) for different time points. The blots are representative of three independent experiments. versed the sensitivity to inhibition of phosphorylation at Tyr-1068 and Tyr-1086 but had no effect at Tyr-1148 and Tyr-1173.
DISCUSSION
Early studies using 1-phenyl-2-decanoylamino-3-morpholinopropanol, a first generation glucosylceramide synthase inhibitor, demonstrated that glucosylceramide-based glycosphingolipids were potent regulators of phospholipase C-stimulated inositol 1,4,5-trisphophate formation (14, 15) . These studies were limited by the lack of specificity and limited activity of 1-phenyl-2-decanoylamino-3-morpholinopropanol, which caused secondary increases in cell ceramide content via inhibition of 1-O-acylceramide synthase (16) . More recently, D-tEtDO-P4 was employed to more specifically evaluate the glycosphingolipid effect on phospholipase C (11). In this study it was determined that the enhanced formation of inositol 1,4,5-trisphosphate was secondary to an induction of tyrosine phosphorylation of phospholipase C-␥1. These changes occurred in the absence of secondary increases in ceramide levels. Increased phospholipase C-␥1 phosphorylation and inositol 1,4,5-trisphosphate formation were observed in the absence of agonist stimulation, but these changes were enhanced in the presence of bradykinin. Glycosphingolipid depletion did not alter the expression of any isoform of phospholipase C, nor did it change the expression of other raft-associated proteins, including Ras, c-Raf-1, eNOS, and annexin II. Finally, the changes in phospholipase C-␥1 phosphorylation and inositol 1,4,5-trisphosphate formation were consistently increased as a function of D-t-EtDO-P4 concentration and time following bradykinin stimulation (11) . Both changes were maximal at 100 nM D-t-EtDO-P4 and at 2 min following 2 M bradykinin exposure.
Although these observations were consistent with a possible direct interaction between a glucosylceramide-based glycolipid and phospholipase C-␥1, such an interaction would be unlikely given the known localization of the glycolipids and the phospholipase within cells. The former is typically localized to the outer plasma membrane leaflet, and the latter is recruited to the inner plasma membrane following agonist stimulation. Phospholipase C-␥1 stimulation can result from activation of G protein-coupled receptors by agonists such as bradykinin or may result from stimulation of receptor tyrosine kinases such as the EGF receptor. In the current model of G protein-coupled receptor activation, phospholipase C-␥1 phosphorylation is secondary to the activation of the receptor tyrosine kinase via Src kinase (17) . For this reason, the role of Src kinase in the glycosphingolipid-dependent change in phospholipase C activity was evaluated.
Src kinase activity was increased following exposure to D-tEtDO-P4. The increase in kinase activity was secondary to glycosphingolipid depletion, because the inactive erythro enantiomer, D-e-EtDO-P4, was without effect. The change in kinase activity was biphasic with the maximal effect observed at100 nM inhibitor, independent of time of exposure. This concentration response paralleled that previously observed for phospholipase C-␥1 phosphorylation and inositol 1,4,5-trisphosphate formation. The basis for the biphasic change in Src kinase activity is not obvious from the present data. Although the The lysate samples were generated as described under "Experimental Procedures." Immunoprecipitation (500 g of lysate protein) was performed using a rabbit polyclonal anti-phosphotyrosine antibody (4 g/ml). The immunoprecipitates were then resolved by SDS-PAGE (4 -13%) and analyzed by Western blotting using a mouse monoclonal antibody against phospholipase C-␥1 (0.1 g/ml) (upper panels). The cellular expression of phospholipase C-␥1 (10 g of lysate protein, lower panels) was determined by Western blotting using a mouse anti-phospholipase C-␥1 antibody (0.1 g/ml). A, control cells were treated with or without 0.1 M PP2 for 12 h and then stimulated with or without EGF (50 ng/ml) for different time points. B, D-t-EtDO-P4-treated cells (100 nM) were incubated with or without 0.1 M PP2 for 12 h and then stimulated with or without EGF (50 ng/ml) for different time points. The blots are representative of three independent experiments. FIG. 8. The sensitivity of EGF receptor carboxyl-terminal tyrosine phosphorylation to PP2 is reversible in glycosphingolipid-depleted ECV304 cells. Cells cultured in the presence or absence of 100 nM D-t-EtDO-P4 for 24 h were exposed to 0.1 M AG1478 for another 12 h and then stimulated with 50 ng/ml EGF for different time intervals as indicated. Equal amounts of whole cell lysate were subjected to Western blot analysis. A, the membrane loaded with 30 g of lysate protein was probed with a polyclonal phosphospecific anti-human EGF receptor (pY1068) antibody. B, the membrane loaded with 30 g of lysate protein was probed with a polyclonal phosphospecific antihuman EGF-R (pY1086) antibody. C, the membrane loaded with 30 g of lysate protein was probed with a polyclonal phosphospecific antihuman EGF-R (pY1148) antibody. D, the membrane loaded with 30 g of lysate protein was probed with a polyclonal phosphospecific antihuman EGF-R (pY1173) antibody. E, the membrane loaded with10 g of lysate protein was probed with a monoclonal anti-human EGF receptor antibody. The blots are representative of three different experiments.
previous study demonstrated that no change in ceramide content is observed at the inhibitor concentrations employed, other glucosylceramide-based glycosphingolipids may demonstrate a different concentration-dependent relationship. An understanding of the relationship between these glycosphingolipids and Src kinase activity will require further study (11) .
The increase in Src kinase activity was accompanied by a decrease in phosphorylation of Tyr-529 and an increase at Tyr-418. These changes are consistent with a current model of Src kinase activation in which the phosphorylation of Tyr-529 is associated with the closed inactive state and phosphorylation of Tyr-418 is associated with the active state of the kinase. These changes in phosphorylation were observed in the absence of agonist stimulation and were enhanced as a function of bradykinin concentration and time following agonist exposure. The Src kinase inhibitor PP2 enhanced Tyr-529 and inhibited Tyr-418 phosphorylation as well as Src kinase activity. These effects were mitigated by D-t-EtDO-P4 but unaltered by the inactive enantiomer D-e-EtDO-P4.
The role of glycosphingolipid depletion in mediating EGFstimulated phospholipase C-␥1 phosphorylation was subsequently studied. Phosphorylation was increased in a time-and concentration-dependent manner in response to EGF. The phosphorylation was increased in the presence of D-t-EtDO-P4 but blocked by the Src kinase inhibitor PP2. The transactivation of the EGF receptor in response to bradykinin was manifest by an increase in phosphorylation of Tyr-1068 and Tyr-1173. Glycolipid depletion by D-t-EtDO-P4, however, increased Tyr-1068 phosphorylation but decreased Tyr-1173 phosphorylation. Stimulation by EGF induced autophosphorylation of EGF receptor at Tyr-1068, Tyr-1086, Tyr-1148, and Tyr-1173. However, D-t-EtDO-P4 was primarily associated with an increase in autophosphorylation only at Tyr-1068 and Tyr-1086. This observation was somewhat surprising, because phospholipase C-␥1 activation has been tied to phosphorylation of Tyr-1173 (18) . Clearly, Tyr-1173 phosphorylation alone is not sufficient to explain activation of phospholipase C-␥1.
The enhanced activation of phospholipase C-␥1 in the setting of glycosphingolipid depletion is perhaps best explained by changes in EGF receptor activity. In the current model of G protein receptor-coupled activation of this growth factor receptor, Src kinase serves as a transactivator for the EGF receptor. The current study presents evidence in support of enhanced Src kinase activity both by direct measurements of the kinase and the secondary changes in Tyr-529 and Tyr-418. These changes appear to occur in addition to but independent of direct interactions with the EGF receptor. Several studies have now implicated the association of most every non-receptor tyrosine kinase with glycosphingolipids. These include c-Src (19) , Lyk, Fyn (20) , Lyn (21, 22) , Yes (23), Cbl (24), FAK (19) , and Csk (25) . These studies have either localized these tyrosine kinases in raft fractions by density gradient separations or have coimmunoprecipitated these kinases with anti-glycosphingolipid antibodies. Signal transduction of non-receptor tyrosine kinases has also been demonstrated in association with several glycosphingolipids. This includes the activation of c-Src by exogenous GM3 (25) , the activation of Lyn by anti-ganglioside GD3 antibody (22) , activation of Lck with exogenous GM1 (26) , the activation of Lyn with anti-␣GalGD1b antibody (27) , and the activation of Yes by the globotriaosylceramide binding toxin shiga toxin (23) . The mechanism responsible for the regulation of non-receptor tyrosine kinases by glycosphingolipids is not understood. In general glycosphingolipids affect the physical properties of lipid rafts and thus may serve to activate raft-associated enzymes by allowing molecules to physically associate, perhaps by coalescence. Alternatively, they may function to exclude molecules that negatively regulate tyrosine kinase activity, such as Csk, from associating with the nonreceptor tyrosine kinase (25) . It also remains to be determined whether glycosphingolipids regulate these tyrosine kinases directly or do so through adaptor molecules.
Glycosphingolipids and gangliosides in particular have been recognized as independent regulators of growth factor receptors as well. The increase in phosphorylation of phospholipase C-␥1 in the presence of the Src kinase inhibitor PP2 and D-tEtDO-P4 are consistent with a role for glycosphingolipids in mediating the changes in phospholipase C activity independent of changes in Src activity. Three models have been proposed for a direct regulation of growth factor receptors by gangliosides (28) . These models include a direct interaction of the growth factor with the ganglioside, the regulation of receptor dimerization by ganglioside, and the modulation of receptor activation state and subcellular localization by ganglioside. The use of specific inhibitors of glucosylceramide synthase provides an alternative method for evaluating these possibilities. Although the purpose of the present study was not to distinguish among these various models, the data suggest that ganglioside ligand interactions and dimerization alone are insufficient to explain the results. The former is unlikely because changes in EGF receptor phosphorylation and phospholipase C-␥1 phosphorylation were observed in the absence of EGF. The latter model is unlikely, because the effects of D-t-EtDO-P4 treatment were specific for particular Tyr residues. This would be unlikely if receptor dimerization were specifically enhanced.
